허혈성 뇌졸중환자의 헤파린 주입량과 주입기간에 영향을 미치는 임상적 요인

국문 초록 (Abstract)

헤파린이 1941년 Hedenius에 의해 처음 소개된 이후 급성
기 색전성 뇌졸중의 재발 감소에 효과가 있다는 연구도 있지만,
메타분석에서 인정받지는 못했고(Paciaroni, Agnelli, Micheli,
& Caso, 2007), 진행성 뇌졸중의 경우에도 효과가 입
증되지는 않았다(Roden-Jullig & Britton, 2000). 이에 따라
허혈성 뇌졸중의 치료에 정맥주사 헤파린의 사용이 감소하였
는데, 1988년부터 2001년까지 북미의 신경과 전문의를 대상
으로 한 연구에서 색전증을 제외한 모든 유형의 뇌졸중에서
정맥주사 헤파린의 사용의도가 종전에 비해 감소한 결과를 가
져왔다(Al-Sadat, Sunbulli, & Chaturvedi, 2002).

목차 (Table of Contents)

• 서 론
• 연구 방법
• 결 과
• 논 의
• 결론 및 제언

참고문헌 (Reference)

1 성영희, "급성뇌경색 환자에서 국내 신경과 전문의의 정맥내 헤파린 투여 사용 실태" 대한뇌졸중학회 5 (5): 151-156, 2003

2 윤성상, "급성기 허혈성 뇌졸중에서 10개 교육병원의 정맥주사 헤파린 이용 실태" 대한신경과학회 23 (23): 446-450, 2005

3 Toth, C., "Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke" 33 : 670-674, 2002

4 Al-Sadat, A., "Use of intravenous heparin by North American neurologists: Do the data matter?" 33 : 1574-1577, 2002

5 Song, H. J., "Use of heparin nomogram in acute ischemic stroke patients" 5 : 181-185, 2001

6 Gonzalez-Conejero, R., "Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients" 37 : 2288-2293, 2006

7 Ferroni, P., "Platelet activation in type 2 diabetes mellitus" 2 : 1282-1291, 2004

8 Tassies,D., "Pharmacogenetics of antithrombotic drugs" 12 : 2425-2435, 2006

9 Marin, F., "Pharmacogenetics in cardiovascular antithrombotic therapy" 3 : 357-364, 2005

10 Freedman,M.D., "Pharmacodynamics, clinical indications, and adverse effects of heparin" 32 : 584-596, 1992

11 Laing, S. P., "Mortality from heart disease in a cohort of 23,000 patients with insulin- treated diabetes" 46 : 760-765, 2003

12 Alvarez-Sabin, J., "Impact of admission hyperglycemia on stroke outcome after thrombolysis: Risk stratification in relation to time to reperfusion" 35 : 2493-2498, 2004

13 Stegenga, M. E., "Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans" 55 : 1807-1812, 2006

14 Hansen, H. R., "Hyperglycemia accelerates arterial thrombus formation and attenuates the antithrombotic response to endotoxin in mice" 18 : 627-636, 2007

15 Hirsh, J., "Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety" 102 (102): 337s-351s, 1992

16 Adams, H. P. Jr., "Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association" 34 : 1056-1083, 2003

17 Adams, H. P. Jr., "Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists" 38 : 1655-1711, 2007

18 Lindley, R. I., "Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction" 13 : 235-246, 2004

19 Valles, J., "Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity" 97 : 350-355, 1998

20 Paciaroni, M., "Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: A meta-analysis of randomized controlled trials" 38 : 423-430, 2007

21 Vaidyula, V. R., "Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand" 55 : 202-208, 2006

22 Roden-Jullig, A., "Effectiveness of heparin treatment for progressing ischaemic stroke: Before and after study" 248 : 287-291, 2000

23 Schmidt, W. P., "Determinants of IV heparin treatment in patients with ischemic stroke" 63 : 2407-2409, 2004

24 Sagesaka, T., "Anemia as a risk factor of hemorrhagic tendency during surgery" 26 : 103-109, 2000

25 Bruno, A., "Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial" 59 : 669-674, 2002

26 Cohen,R.A., "ATVB in focus: Diabetic vascular disease: Pathophysiological mechanisms in the diabetic milieu and therapeutic implications" 24 : 1340-1341, 2004

27 Cruickshank, M. K., "A standard heparin nomogram for the management of heparin therapy" 151 : 333-337, 1991